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Abstract
Adaptation is normally viewed as the enemy of the antibiotic discovery and development process because adaptation
among pathogens to antibiotic exposure leads to resistance. We present a method here that, in contrast, exploits the power
of adaptation among antibiotic producers to accelerate the discovery of antibiotics. A competition-based adaptive
laboratory evolution scheme is presented whereby an antibiotic-producing microorganism is competed against a target
pathogen and serially passed over time until the producer evolves the ability to synthesize a chemical entity that inhibits
growth of the pathogen. When multiple Streptomyces clavuligerus replicates were adaptively evolved against methicillin-
resistant Staphylococcus aureus N315 in this manner, a strain emerged that acquired the ability to constitutively produce
holomycin. In contrast, no holomycin could be detected from the unevolved wild-type strain. Moreover, genome re-
sequencing revealed that the evolved strain had lost pSCL4, a large 1.8 Mbp plasmid, and acquired several single nucleotide
polymorphisms in genes that have been shown to affect secondary metabolite biosynthesis. These results demonstrate that
competition-based adaptive laboratory evolution can constitute a platform to create mutants that overproduce known
antibiotics and possibly to discover new compounds as well.
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Introduction
The past ten to fifteen years have seen an alarming increase in
the number of infections caused by bacteria such as Staphylococcus
aureus, Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas
aeruginosa, and Mycobacterium tuberculosis that have evolved resistance
to at least one antibiotic [1]. The majority of antibiotics that have
been used to treat infections caused by these pathogens are natural
products or their semi-synthetic derivatives that originated from
bacteria of the order Actinomycetales, in particular the genus
Streptomyces [2,3], which are distributed worldwide and are
commonly found in soil and marine sediments. This environmen-
tal habitat and their ability to produce numerous secondary
metabolites have raised many questions about the ecological role
of antibiotic production [4,5,6], but one prevailing hypothesis is
that this ability arose as a product of evolution to serve as a
defensive mechanism against microbial competitors [5,7]. Many
new antibiotics were isolated from actinomycetes between the late
1940s and the late 1960s, a period which came to be known as the
Golden Age of antibiotic discovery, but this rate plummeted
thereafter due in large part to the frequent rediscovery of existing
compounds that are highly abundant. Recent genome sequence
information, however, suggests that this source is still not yet
exhausted. Whole-genome sequencing of several actinomycetes
[8,9,10,11,12] has revealed that each member can synthesize on
average 20–30 bioactive small molecules, but only a small fraction
of these molecules have ever been detected under various culture
conditions. Cloning and heterologous expression of biosynthetic
gene clusters [13,14], interfering with regulatory pathways
[15,16,17,18,19], varying culture conditions [20,21], co-culturing
two or more organisms together [22,23,24,25,26,27,28], and other
strategies [29] have all been employed in attempts to stimulate the
production of new compounds.
In the laboratory, the genetic and molecular mechanisms
underlying a pathogen’s ability to develop resistance are frequently
studied by serially passing the pathogen over time in media
containing increasing concentrations of an antibiotic
[30,31,32,33,34]. This evolution-based strategy leads to mutants
with higher levels of resistance when compared to the parental,
unevolved clone or to any spontaneous mutants that might have
arisen at the outset of the evolution. This general process in which
an organism is serially passed against a certain selection pressure to
promote adaptation to a new environment is commonly referred
to as adaptive (laboratory) evolution, and has been used to
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resistance. Several examples include the study of Escherichia coli as it
evolves in glucose minimal media in the laboratory over multiple
decades [35,36], as it adapts to growth on alternative carbon
sources such as glycerol and lactate [37,38], and as it adjusts to the
deletion of phosphoglucoisomerase (pgi), a major metabolic gene
[39,40]. Adaptive evolution has also found uses as a laboratory
tool to investigate mechanisms of ethanol tolerance [41,42,43] and
osmotic stress [44], to create strains of Geobacter sulfurreducens that
reduce iron oxide more rapidly [45], to improve yields of
commercially-valuable chemicals from metabolically-engineered
microbial strains [46,47], and to examine factors important to
virulence and host adaptation among different pathogens
[48,49,50]. We emphasize here the importance of time and serial
passage to this process: these new phenotypes arose only after
adaptive laboratory evolution and not after initial, short-term
exposure to the selection pressure.
At its core, the current state of antibiotic therapy is one in which
a group of pathogenic microorganisms have developed resistance
to compounds produced by and isolated from a different group of
microorganisms. At the same time, adaptive laboratory evolution
is an established technique to generate new phenotypes. Against
this backdrop, we hypothesized that microorganisms with
extensive secondary metabolism such as actinomycetes could
adaptively evolve in the laboratory to produce new antibacterial
compounds if they had to compete over time against a drug-
resistant pathogen, compounds not normally produced by the
wild-type. The use of adaptive laboratory evolution distinguishes
our work from prior studies that utilized co-cultures to stimulate
production of new compounds [22,23,24,25,26,27,28] but did not
utilize repeated serial passage of one organism against another, as
was done here. We tested our hypothesis by adaptively evolving
multiple colonies of Streptomyces clavuligerus against methicillin-
resistant Staphylococcus aureus (MRSA) N315 [51] over several
months in the laboratory. We isolated several evolved S. clavuligerus
strains during this time, identified the bioactive compound
produced by one of them, and resequenced the same strain to
detect the genomic mutations that arose during the adaptive
evolutionary process.
Results
Overview of the method
The adaptive laboratory evolution protocol developed here
(Figure 1) comprises a total of five steps, four of which are
performed repeatedly. An inoculum of an antibiotic producer is
first deposited onto an agar plate and allowed to grow for several
days (Step 1). An inoculum of the target pathogen is then spread
onto the plate such that it covers the remaining exposed agar
surface and, crucially, completely surrounds and contacts the
antibiotic producer (Step 2). Any zone of inhibition (ZOI)
surrounding the antibiotic producer initially should be negligible.
The plate is then incubated for another several days in order to
culture the two bacteria together (Step 3). It is presumed that, over
time, competitive exclusion will stimulate the antibiotic producer
to synthesize a chemical entity that will inhibit growth of the
competing pathogen. After incubation, each replicate of the
evolving antibiotic producer is separated from the target pathogen
(Step 4). Single colonies are then selected and transferred to a new
agar plate (Step 5) to start a new cycle. The latter four steps are
performed repeatedly until colonies of the antibiotic producer are
isolated that produce a stable ZOI that is larger than any
surrounding the original parental clone. During each cycle, the
inoculum containing the target pathogen that is used to challenge
the antibiotic producer (Step 2) comes from fresh cultures that
have had no prior contact with the producer. This requirement
ensures that the antibiotic producer faces the same selection
pressure during each cycle and that only the producer, not the
Figure 1. The five-step competition-based adaptive evolution scheme developed here to generate antimicrobial compounds.
Antibiotic producing microorganisms are depicted in blue and competing pathogens in yellow. An evolution would end when a larger zone of
inhibition (ZOI) appears around an evolved replicate of the antibiotic producer than any ZOI that might surround the unevolved wild-type. As a
control, an additional set of replicates are evolved according to the same scheme but are not exposed to the pathogen until the end.
doi:10.1371/journal.pone.0033727.g001
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evolution. The design of this procedure is similar to one used to
select for certain Dictyostelium discoideum mutants from a mixed
population of the same organism [52], but the procedure
presented here differs in three critical aspects: 1) two different
organisms, rather than two subpopulations of the same organism,
are made to compete against each other, 2) one of the two
organisms has a proven ability to produce small molecule
inhibitors against the other, and 3) the subsequent use of analytical
and organic chemistry tools to elucidate the structures of the
bioactive molecules.
S. clavuligerus can evolve along different evolutionary
trajectories when competed against MRSA N315 over
time
We tested this adaptive laboratory evolution protocol by
competingandadaptivelyevolvingtwenty-eightStreptomyces clavuligerus
replicates against MRSA strain N315 [51] over 4 months, collecting
fourteen isolates during this period that appeared to produce a larger
ZOI when compared to the small zone surrounding the parental,
wild-type strain. These fourteen strains have been designated clavu1
through clavu12, NL2-c4, and ReIN. The first isolates, clavu1,
clavu2, NL2-c4, and ReIN, were collected after six weeks and three
serial passages. The last isolates, clavu10, clavu11, and clavu12, were
collected after four months and eight serial passages. The largest,
most stable ZOIs were produced by clavu7, clavu9, clavu10, NL2-c4,
and ReIN; thus, we focused our subsequent chemical analysis efforts
on these strains. Images of wild-type S. clavuligerus and these five
evolved isolates co-cultured with S. aureus 8325-4, a drug-sensitive
research strain, and MRSA N315 are shown in Figure 2.
To control against effects arising solely from long-term growth on
agar and not from exposure to MRSA N315, we also evolved
fourteen additional replicates according to this same procedure but
did not expose them to MRSA N315 at any point during their
evolution. After three months, we tested the replicates to investigate
whether any of them had developed the ability to produce a larger
ZOI against MRSA N315, despite the absence of prior contact with
the pathogen, than the small, ,1 mm ZOI seen surrounding the
unevolved clone (Figure 2). We defined the size of a ZOI here as
the distance from the edge of a S. clavuligerus colony to the nearest
MRSA N315 colony. One control replicate produced a slightly
larger ZOI(1–2 mm)butthe remaining thirteen didnot; the sizes of
the clearing zone surrounding these latter thirteen strains remained
unchangedorweresmallerwhencomparedtotheZOIsurrounding
theunevolved clone (FigureS1). In contrast, the ZOIs surrounding
the fourteen strains evolved against MRSA N315 ranged from two
to six millimeters. Several of these strains are shown in Figure 2.
These data suggest that the ZOIs surrounding the fourteen strains
evolved against MRSA N315 arose from exposure to the pathogen
and not from long-term growth on the TSA plates (p=0.0071; two-
tailed Fisher’s Exact Test).
The antibiotic holomycin can be detected in the ZOI
surrounding clavu7 but not in the ZOI surrounding
parental, wild-type S. clavuligerus, or four of the other
evolved strains
We next focused on one isolate, clavu7, and performed a
detailed chemical analysis to establish the identities of the
antibacterial compounds that were present in its ZOI. The
methanol extracts from clavu7 ZOIs semi-purified by solid-phase
Figure 2. Images of unevolved, wild-type S. clavuligerus and five strains (clavu7, clavu9, clavu10, NL2-c4, and ReIN) adaptively
evolved against MRSA N315. The top half of each panel shows each strain plated against drug-sensitive S. aureus 8325-4 while the bottom half
shows the same strain plated against MRSA N315. Top left: wild-type S. clavuligerus. Top middle: clavu7. Top right: clavu9. Bottom left: clavu10.
Bottom middle: NL2-c4. Bottom right: ReIN. The images were taken 24 hrs after S. aureus 8325-4 and MRSA N315 were plated against the six strains.
doi:10.1371/journal.pone.0033727.g002
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collected in half-minute intervals over the entire course of the
separation. Only one of these fractions, eluting at 11.8 minutes,
showed bioactivity against MRSA N315 and corresponded to a
single peak in the chromatogram (Figure 3). Moreover, this peak
was not present when identical-sized agar zones surrounding wild-
type S. clavuligerus colonies were extracted in the same manner
(Figure 3). Comparative mass spectrometric (MS) analysis
revealed that an ion with m/z 388 eluted from both samples at
this time point but that the clavu7 sample had an additional ion
with m/z 215 ([M+H]
+)( Figure 3).
We isolated the compound with m/z 215 from the compound
with m/z 388 to establish definitively whether it had antibacterial
activity (Figure S2). The isolated m/z 215 compound displayed
clear bioactivity against MRSA N315 whereas the m/z 388
compound did not (Figure 3). We then sought to determine the
structure of this bioactive compound by high-resolution MS and
MS/MS (Figure S3). The molecular ion was found to be
C7H7N2O2S2 ([M+H]
+; exact mass: 214.9941), which is identical
to that of holomycin, an antibiotic S. clavuligerus is known to
produce [53]. Moreover, the fragment at m/z 173 in the high-
resolution MS/MS (Figure S3), having the molecular formula
C7H7N2O2S2 (exact mass: 172.9836), matched the fragmentation
pattern reported previously for holomycin and corresponds to the
core dithiolopyrrolone holothin structure [54,55]. The identity of
the compound was subsequently confirmed by comparing the
HPLC-MS characteristics of our unknown with that of pure
holomycin: both had the same elution time and same MS and
MS/MS fragmentation patterns (Figure 3).
Clavu7 produces holomycin constitutively. Even when clavu7
colonies were not challenged by MRSA N315, we could still detect
holomycin in extracts of the agar zones immediately surrounding
clavu7 colonies. The yield from a set of 30 clavu7 plates was
routinely 3–4 nmol, but this amount was affected by batch-to-
batch variability in the growth medium.
Having established a definitive protocol to isolate and identify
holomycin, we next examined whether clavu9, clavu10, NL2-c4,
and ReIN produce this compound as well. When their
surrounding ZOIs were extracted and analyzed via LC-MS using
the same procedure developed for clavu7, we could detect low
amounts of holomycin from NL2-c4. When this fraction was
collected off the HPLC and tested against MRSA N315, however,
it was not bioactive. No holomycin could be detected during LC-
MS analysis of extracts from the other strains. We therefore
conclude that clavu9, clavu10, NL2-c4, and ReIN produce a
different suite of bioactive compounds than clavu7 does.
At least six mutations distinguish the genome of clavu7
from the reference genome: the loss of a 1.8 megabase
(Mbp) plasmid and five single nucleotide polymorphisms
(SNPs)
Since biosynthetic gene clusters encode antibiotic production, we
sequenced clavu7 and the parental, wild-type S. clavuligerus strain to
identify any mutations that might have arisen during adaptation.
We detected six mutations in clavu7 (Table 1). Of note, we
confirmed that the wild-type S. clavuligerus strain we used to start the
evolutions (ATCC 27064) contained a 1.8 Mbp linear plasmid
designated pSCL4 [10] by mapping Illumina sequence data
collected for the wild-type strain onto the published reference
sequence (Figure4A). On the other hand,there was negligible read
coverage of the megaplasmid when Illumina data from clavu7 was
mapped onto the same reference sequence (Figure 4B). Further-
more, we could successfully PCR amplify five amplicons located on
pSCL4 from genomic DNA extracted from wild-type S. clavuligerus
butnot from clavu7(Figure4C).Bothofthesedata sets supportthe
concept that clavu7 has lost pSCL4. The size of the wild-type S.
clavuligerus chromosome is approximately 6.8 Mbp [10,12]; there-
fore, the loss of pSCL4 reduced the total clavu7 genome size by
21%.
This observation prompted us to investigate whether pSCL4
had disappeared from any of the other strains evolved against
MRSA N315 or from the fourteen control replicates evolved for
the same amount of time. A possible link between the loss of an
unidentified extrachromosomal element, which we hypothesized
might have been pSCL4, and a holomycin-producing S. clavuligerus
mutant motivated this investigation [56]. We attempted to detect
the megaplasmid by PCR amplification using the same five primer
sets that were used to verify the loss of pSCL4 from clavu7 (Table
S1). We could not detect pSCL4 in clavu9, and we could detect
only the rightmost portion of it in clavu10 (Figure S4). In
contrast, we could detect all five amplicons in NL2-c4 and ReIN,
and in all fourteen control replicates (Figure S4). These data do
not support a link between the loss of pSCL4 and holomycin
overproduction. On the other hand, the data suggest that exposure
to MRSA N315 might have promoted the loss of pSCL4 from
clavu7 and clavu9 since all fourteen control replicates still retain
the megaplasmid (p=0.039; two-tailed Fisher’s Exact Test).
In addition to loss of pSCL4, a second notable mutation is the
nonsynonymous SNP in ACV synthetase (pcbAB), raising the
possibility that production of b-lactam antibiotics might be
perturbed in clavu7. This enzyme is a three-module nonribosomal
peptide synthetase (NRPS) that catalyzes the second step in b-
lactam biosynthesis in actinomycetes, the condensation of a-
aminoadipic acid, L-cysteine, and L-valine to form the tripeptide L-
d-a-AAA-L-cysteinyl-D-valine (LLD-ACV) [57]. The pathways
downstream of LLD-ACV eventually lead to the biosynthesis of
several major b-lactams such as penicillin G, cephalosporin C, and
cephamycin C. Bioinformatics analysis of the S. clavuligerus ACV
synthetase suggests that the SNP occurs within the second of three
adenylation domains (Figure S5).
Besides ACV synthetase, there are two SNPs in genes involved
in primary metabolism, malate dehydrogenase (mdh) and glycosyl
hydrolase. The annotations for both suggest that they are
synonymous mutations. Another SNP is located in a putative
gene containing a WD-40 repeat unit and would result in a proline
to serine substitution. The final SNP is a nonsynonymous mutation
in pyrroloquinoline quinone biosynthesis protein B (pqqB).
The holomycin biosynthetic gene cluster in S. clavuligerus has
recently been identified [58], but we could not detect any
mutations within this cluster in clavu7.
Discussion
Adaptation is normally seen as the enemy of the antibiotic
discovery and development process in part because adaptation
among pathogens leads to resistance. In contrast, the method
presented here exploits the power of adaptation among antibiotic
producers to accelerate the discovery of antimicrobial compounds.
Accordingly, there are three major findings of this study. The first
is the development of a novel competition-based adaptive
laboratory evolution method to elicit the production of antibac-
terial compounds. The use of adaptive evolution distinguishes this
method from prior studies aimed at stimulating secondary
metabolite production through the co-culture of two or more
organisms [22,23,24,25,26,27,28]. In such studies, two or more
organisms are normally cultured together and the supernatant
assayed for the presence of bioactive compounds not normally
Adaptive Evolution of Sclavu
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33727Figure 3. HPLC-MS data from wild-type S. clavuligerus (black), clavu7 (blue), and clavu7 spiked with holomycin (red). A. HPLC
chromatograms of extracts from the three samples. The arrow indicates the peak corresponding to holomycin, which elutes at approximately
11.8 min. Note that this peak is not detected in extracts from wild-type S. clavuligerus. B. MS total ion monitoring at 11.8 min. There is an intense
peak at m/z 388 in both wild-type S. clavuligerus and clavu7 samples, but an ion with m/z 215 ([M+H]
+), which is holomycin and indicated by the
arrow, can be detected in the clavu7 sample only. Inset. Magnification of the region surrounding m/z 215. C. MS and MS/MS select ion monitoring for
m/z 215 (MS), m/z 197 (MS/MS; SRM) and m/z 388 (MS). The m/z 197 fragment in the MS/MS in particular is a sensitive signature for holomycin. D.
When holomycin and the m/z 388 compound are separated (Figure S1) and tested individually against MRSA N315, only holomycin shows bioactivity.
E. The structure of holomycin. High-resolution MS/MS indicates that the m/z 197 fragment corresponds to loss of H2O ([M2H2O+H]
+, Figure S3).
Abbreviations: SIM, select ion monitoring; SRM, selected reaction monitoring.
doi:10.1371/journal.pone.0033727.g003
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bioactive compound is detected from the mixed culture, the
supernatant is typically discarded. In the method developed here,
however, the absence of bioactivity after the initial co-culture does
not signal the end of the experimental process. Instead, we isolate
the microorganism of interest from the mixed culture and then
compete it against the second (target) microorganism a second
time. This cycle of co-culture and isolation repeats itself over
multiple rounds until bioactivity can be detected, and is a
laboratory-based implementation of the competitive exclusion
principle [59,60,61]. The second is a proof-of-principle demon-
stration of the method, exhibited through the isolation of a set of
evolved S. clavuligerus mutants that produce larger ZOIs against
MRSA N315 than the parental wild-type clone does, one of which
produces bioactive amounts of holomycin. The third is a
demonstration through the same mutant that a very large plasmid
constituting 21% of the genome content of S. clavuligerus, pSCL4,
can be successfully removed from the wild-type organism. This
megaplasmid contains 25 clusters that encode putative secondary
metabolites [10] but, interestingly, clavu7 evolved against MRSA
N315 by eliminating the plasmid rather than utilizing any of the
25 possible products encoded by the plasmid-borne clusters.
Holomycin is a member of the pyrrothine class of antibiotics
and has been shown to inhibit growth of several drug-sensitive and
drug-resistant strains of S. aureus [62]. Although the precise
regulatory programming that controls holomycin biosynthesis in S.
clavuligerus remains to be elucidated, certain defined mutants in
which genes catalyzing the late steps in clavulanic acid biosynthesis
have been deleted have been shown to overproduce holomycin
[54]. The data presented here, however, point to several other
factors that might boost holomycin production. The SNP in pqqB,
pyrroloquinoline quinone biosynthesis protein B, is particularly
noteworthy because PqqB is involved in the biosynthesis of
pyrroloquinoline quinone [63], a redox cofactor for several
bacterial dehydrogenases such as glucose dehydrogenase, metha-
nol dehydrogenase, and possibly several other alcohol dehydroge-
nases [63,64,65]. Intriguingly, a pqqB deletion mutant of
Pseudomonas fluorescens overproduces the antibiotic/antifungal
compound pyoluteorin [66], suggesting that a connection exists
between the pqq operon and secondary metabolite production in
bacteria. Based on these data, we speculate the following
mechanism to explain the increased holomycin production seen
in clavu7. First, the SNP in pqqB perturbs the biosynthesis of
pyrroloquinoline quinone, which in turn perturbs the enzymatic
activity of multiple dehydrogenases, including possibly malate
dehydrogenase since clavu7 contains a SNP in this enzyme as well.
This mutant form of malate dehydrogenase is then able to
synthesize greater amounts of oxaloacetate, the TCA cycle
precursor to aspartate and by extension to cysteine. Because each
molecule of holomycin is formed from two molecules of cysteine
[58], higher cysteine levels would allow clavu7 to biosynthesize
larger quantities of the antibiotic. Additional data would be
needed to confirm this proposed mechanism.
The appearance of other SNPs in clavu7 suggests that other
aspects of primary and secondary metabolism are also perturbed
in this strain. According to current genome annotations for S.
clavuligerus (GenBank accession numbers ADGD00000000 and
ABJH00000000), the SNP in ACV synthetase would result in a
valine to leucine substitution within the adenylation domain of
the second module to the N-terminal side of a conserved amino
acid binding pocket (Figure S5). Consequently, the substitution
does not appear to affect any of the eight or ten critical residues
within the binding pocket that mediate amino acid specificity
[67,68], suggesting that cysteine continues to be incorporated into
the second module of the mutant ACV synthetase. Given this
assessment, this SNP might be a neutral mutation; however, data
from other adaptive evolution experiments, most involving the
model bacterium Escherichia coli, argue against this viewpoint. For
example, when all combinations of mutations that were detected
after several adaptive evolution studies were introduced back into
the parental strain, every mutation was found to impact the
endpoint phenotype either singly or in combination [37,38,39].
For this reason, we posit that the SNP in ACV synthetase does
not change the substrate specificity of the module but that it
might affect another property of the enzyme such as reaction
kinetics.
Proteins containing WD-40 motifs are common scaffolding
proteins in eukaryotes that mediate protein-protein interactions
[69,70]. These proteins also appear frequently in actinobacteria
(especially actinomycetes), cyanobacteria, and proteobacteria;
however, they are rare among other prokaryotes, so the
appearance of a SNP in a WD-40 containing protein in clavu7
(Table 1: SCLAV_2674) is notable. A WD motif consists of
approximately 40 amino acids that often terminates in a
tryptophan-aspartate (W-D) dipeptide, and there is another
characteristic dipeptide sequence (VH, AH, SH, or GH) located
approximately 27 base pairs to the N-terminal side of the WD
marker [71]. The ,27 amino acids between the two markers form
a conserved core region [71]. A single WD-40 containing protein
normally has 4–16 WD-40 units, and there appears to be three of
them in SCLAV_2674 (Figure S6). The SNP in SCLAV_2674 in
clavu7 results in a P366S amino acid substitution that is located to
the N-terminal side of the three repeats. In eukaryotes, proteins
containing WD-40 motifs are known to play a role in diverse
processes such as signaling, cell cycle control, and cytoskeleton
assembly [69,70], and we speculate that they might play a role in
Table 1. List of mutations detected in clavu7.
Broad locus ID DSM locus ID Annotation SNP
1 Loss of pSCL4 megaplasmid
2 SSCG_02612 SCLAV_2674 WD-40 repeat-containing protein C1096T
3 SSCG_05972 SCLAV_3742 malate dehydrogenase C570A
4 SSCG_00146 SCLAV_4200 N-(5-amino-5-carboxypentanoyl)-L-cysteinyl-D-valine synthase G4573C
5 SSCG_05988 SCLAV_5196 glycosyl hydrolase G1245A
6 SSCG_06722 SCLAV_5104 pyrroloquinoline quinone biosynthesis protein B G433A
The Broad locus IDs are taken from accession number ABJH00000000. The DSM locus IDs are taken from accession number ADGD00000000. The SNP positions are
based on Broad locus IDs.
doi:10.1371/journal.pone.0033727.t001
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33727Figure 4. Alignment of wild-type S. clavuligerus and clavu7 resequencing data to the reference S. clavuligerus ATCC 27064 genome.
A. Alignment of Illumina sequencing data from the wild-type S. clavuligerus strain used in this study to initiate adaptive evolution against MRSA N315.
As expected, the data maps to the entire reference sequence. The encircled region indicates the position of the 1.8 Mbp pSCL4 plasmid. B. Alignment
Adaptive Evolution of Sclavu
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33727the assembly of multi-protein complexes involved in secondary
metabolite biosynthesis as well.
Prior to elimination, several regions from pSCL4 might have
been transferred to the chromosome since some reads from the
Illumina data for clavu7 still mapped to the plasmid sequence
(Figure 4B). This observation does not appear to be an artifact of
library preparation or other aspects of the sample handling and
sequencing process; two different colonies sequenced one year
apart using two different sample preparation protocols and
reagents yielded the same result.
In conclusion, we develop and demonstrate a competition-based
adaptive laboratory evolution method here that pitted S. clavuligerus
against MRSA N315 and show that this method can lead to the
biosynthesis of a known antibiotic, holomycin, that is not produced
in detectable quantities by the wild-type strain when grown under
identical conditions. Looking forward, the strengths of this
approach could extend beyond this particular example. First, this
method is a general, systematic platform technique that in theory
can be used to overproduce or possibly discover new antibacterial
compounds against other pathogens, not just MRSA. Several
possibilities include pathogenic fungi [72], potential biowarfare
agents such as Yersinia pestis and Francisella tularensis, and many drug-
resistant Gram-negative bacteria such as A. baumannii, K.
pneumoniae, and P. aeruginosa. The latter group represents a
particularly intriguing target choice because their extensive drug
resistance profile increases the probability that new chemical
entities would be discovered rather than existing compounds.
Moreover, this method can be applied to other fields besides
medical microbiology since the principal requirement for imple-
mentation is simply the ability to culture both the organism of
interest and the target on the same growth medium. One possible
example is the discovery of agents to control plant pathogens
important to agriculture. Second, parallel evolutions descended
from the same starting clone might lead to different, alternative
phenotypes as replicates traverse multiple paths through the
evolutionary landscape. In the case of antibacterial discovery from
actinomycetes, this phenomenon could lead to the overproduction
or discovery of multiple, different inhibitors for each parental
strain that undergoes adaptive evolution. Indeed, preliminary data
from clavu9, clavu10, ReIN, and NL2-c4 support this viewpoint
since we could not detect bioactive amounts of holomycin from
extracts of these four strains, suggesting that they produce at least
one other bioactive compound. Third, this approach is amenable
to high-throughput implementation through the use of liquid
handlers, colony pickers, and other automated equipment to
evolve and screen multitudes of colonies. Since many commer-
cially valuable natural products are obtained through fermentation
of various actinomycetes, this tactic could provide insights into
new mechanisms to increase their yields – and potentially to lead
to the discovery of new compounds.
Materials and Methods
Bacterial strains
Streptomyces clavuligerus 27064 was purchased from ATCC.
Methicillin-resistant Staphylococcus aureus 8325-4 and N315 were a
gift from Victor Nizet (Univ. of California, San Diego). The strains
clavu1 through clavu12, NL2-c4, and ReIN were all generated
during this study.
Chemicals and supplies
Trypticase soy broth with dextrose (TSB) [Becton Dickinson,
Sparks, MD] and trypticase soy agar (TSA) were used throughout
this study (both 30 g/L) and dissolved in deionized water prior to
autoclaving. To make TSA, we added 18 g/L Bacteriological
Agar (Sigma-Aldrich, St. Louis, MO) to TSB. To extract
holomycin, we used ACS-grade methanol (Fisher Scientific,
Pittsburgh, PA), ExpressPlus 0.22 mm membranes for sterile
filtration (Millipore, Billerica, MA) and Oasis MCX cation
exchange solid-phase extraction (SPE) columns (Waters Corp.,
Waltham, MA). The amount of holomycin we extracted from
ZOIs surrounding clavu7 colonies was affected by batch-to-batch
variability in the TSB even though we always sourced from the
same supplier.
Adaptive evolution protocol
The general, fundamental aspects of the adaptive evolution
protocol developed here is described in the main text and depicted
in Figure 1. This section will focus on specific details concerning
its implementation with respect to S. clavuligerus against MRSA
N315. The steps noted in this section correspond to those shown in
Figure 1.
The S. clavuligerus vs. MRSA N315 evolutions began by
inoculating 50 mL of TSB in a 250 mL triple-baffled flask with
wild-type S. clavuligerus mycelia that were stored in 20% glycerol at
280uC. The flask was capped with a foam plug, placed on top of a
magnetic stir plate and incubated at 30uC. A magnetic stir bar
spinning inside the flask was used for aeration.
After visible growth of the pre-culture, an aliquot was diluted
such that its optical density at 600 nm (OD600) was 0.10–0.13.
Two microliters were then deposited onto each of seven spots
spaced equidistantly on a 100 mm615 mm TSA plate and
incubated at 28uC for three days (Step 1). On the third day, we
plated approximately 150 mL of MRSA N315 suspended in TSB
onto each of the plates (Step 2). The density of the MRSA N315
inocula was 0.01 (range: 0.008–0.013), and care was taken to
ensure that the inocula completely surrounded and came into
contact with each S. clavuligerus colony. At the same time, however,
we attempted to minimize the amount of MRSA N315 inocula
that flowed over the top of the colonies. The plates were again
incubated at 28uC, this time for 5–7 days (Step 3), after which each
S. clavuligerus colony was streaked onto fresh TSA plates to separate
them from MRSA N315 (Step 4). After incubating for another 2–3
days, small fragments from single S. clavuligerus colonies belonging
to each replicate were broken off and transferred to a new TSA
plate such that there were once again seven replicates spaced
equidistantly apart per plate (Step 5). After another 3 days
incubation, fresh MRSA N315 was again plated against the S.
clavuligerus colonies to continue the cycle of adaptive evolution.
Importantly, we serially passed S. clavuligerus only; we did not pass
MRSA N315 along with S. clavuligerus. In other words, the MRSA
N315 that was plated during each cycle came from cultures that
had never come into previous contact with any of the S. clavuligerus
replicates.
of Illumina data from clavu7. There is negligible read coverage for pSCL4. C. PCR amplification of five pSCL4 amplicons and one chromosomal
amplicon from both wild-type S. clavuligerus and clavu7. The five pSCL4 amplicons can be amplified using DNA from wild-type S. clavuligerus as a
template but not from clavu7 DNA, results which reinforce the Illumina sequencing data. The chromosomal amplicon serves as a positive control and
corresponds to the same amplicon used to Sanger sequence the SNP in SSCG_05972 (Table 1).
doi:10.1371/journal.pone.0033727.g004
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manner over a four-month period and collected 14 isolates that
appeared to produce larger ZOIs against MRSA N315 when
compared to wild-type S. clavuligerus. As a control, fourteen
additional replicates were also evolved in this manner, but they
were not exposed to MRSA N315 at any point during their
evolution. To store each evolved isolate long-term, we re-streaked
them on fresh TSA plates, transferred a well-isolated colony into
TSB, and incubated the culture with spinning to enable liquid
growth. Glycerol was then added to aliquots of the mycelia to a
final concentration of 20%. The samples were then frozen and
stored at 280uC.
LC-MS analysis of bioactive components from clavu7
ZOIs and identical-sized zones surrounding wild-type S.
clavuligerus colonies
Frozen clavu7 mycelial stocks were regrown by inoculating
them into 50 mL TSB in 125 mL triple-baffled flasks with
spinning. Once there was visible growth, and as long as the cells
were still in exponential phase, the OD600 of the pre-culture was
adjusted to 0.1–0.13 before plating on TSA. If the density of the
pre-culture corresponded to stationary phase densities, we
discarded the pre-culture and made a new one from frozen stock.
To extract compounds from the ZOI surrounding clavu7
colonies, we first deposited 2 mL of the OD600 0.1–0.13 pre-
cultures onto each of 16 spots on TSA plates. We routinely used 30
such plates every time we carried out an extraction. The plates
were then incubated at 28uC for three days, conditions identical to
those used during adaptive evolution. Because we did not know a
priori whether the bioactive compound produced by clavu7 was
induced by the presence of MRSA N315 or whether it was
produced constitutively, we initially plated MRSA N315 on every
clavu7 plate three days after clavu7 was inoculated. Again, this
step is identical to that used during adaptive evolution (Step 2), but
was later skipped when performing extractions (see below). After
another 24 h incubation, ZOIs surrounding each clavu7 colony
were punched out with a cork borer, collected together along with
the clavu7 colonies, and diced into small pieces. The mixture
comprising macerated agar (ZOIs) and clavu7 colonies was then
extracted with methanol for approximately 30 min with gentle
spinning on a stir plate. The methanol extract was then sterile-
filtered through a 0.22 mm membrane to remove bacteria and
rotavapped at 37uC until 2–3 mL remained. Deionized water was
subsequently added to the concentrated methanol sample
according to the ratio sample:water 1 mL:39 mL (2.5% final
methanol concentration) in order to load the sample onto Oasis
MCX SPE columns. We prepped the SPE column with 4 mL
methanol followed by 4 mL deionized water before loading the
sample. We then washed the SPE column with 2% formic acid in
water and then with 20:80 methanol:water before eluting with
3 mL 70:30 methanol:water. The flow rate was held at
approximately 4 mL/minute. Subsequently, we concentrated the
70:30 methanol:water fraction through use of a speed-vac set to
37uC until 50–100 mL remained.
This semi-purified sample was then subjected to LC-MS and
LC-MS/MS analysis using an Agilent C-18 column (Eclipse XDB-
C18, 5 mm, 4.6 mm6150 mm) attached to a Thermo Finnigan
LCQ Deca system with electrospray ionization in the positive ion
mode. The flow rate was 1.0 mL/minute. With solvent A as 5%
methanol in water and solvent B as 100% methanol, the mobile
phase was: hold 5% B for 2 min; linear gradient to 50% B over
13 min; linear gradient to 95% B over 3 min; hold 95% B for
2 min; linear gradient back to 5% B over 2 min; and hold 5% B
for 3 min. Both methanol and water were HPLC grade. Under
these conditions, holomycin elutes at 11.8 min with detection at
360 nm. For high-resolution MS, we used a Thermo Scientific
LTQ Orbitrap XL mass spectrometer with electrospray ioniza-
tion.
Once we determined the elution time for the bioactive
compound (holomycin) in the HPLC chromatogram and its MS
and MS/MS signatures, we tested whether clavu7 produced it
constitutively or whether its production was induced by the
presence of MRSA N315. To answer this question, we carried out
the extraction protocol described above but did not plate MRSA
N315 against clavu7 on the third day of incubation. All other steps
in the extraction protocol were kept the same. We found that the
LC-MS data remained unchanged. Once we obtained these data,
we no longer plated MRSA N315 against clavu7 during all
subsequent extractions.
As a control, frozen stocks of wild-type S. clavuligerus mycelia
were regrown, plated, extracted, and analyzed via LC-MS and
LC-MS/MS according to the same protocol developed for clavu7.
Bioactivity testing
Fractions were tested for bioactivity by first making a lawn of
MRSA N315 on a TSA plate using an OD600 ,0.01 TSB pre-
culture (range: 0.008 to 0.013). Thirty microliters of the fraction to
be tested was then pipetted onto a 6 mm paper disk, allowed to
dry, and then the disk transferred to the agar plate containing
MRSA N315. After 16–20 h incubation at 30uC, the plate was
visually inspected for the presence of an inhibition zone
surrounding the paper disk.
Alignment of resequencing reads and SNP identification
The reference assembly for wild-type S. clavuligerus ATCC
27064 [10] was obtained from GenBank (accession number:
ADGD00000000) and consisted of 279 contigs. These contigs were
concatenatedtobuildthe referencesequenceforalignment.Illumina
reads from the resequencing runs of both the wild-type and clavu7
were iteratively aligned to this reference using MosaikAligner
(http://bioinformatics.bc.edu/marthlab/Mosaik). The number of
allowed mismatches in the alignment was iteratively increased from
0 to 5 with the unaligned reads used as the input for the subsequent
iteration. The alignments were processed using a custom script
written in-house [37] to obtain the fold coverage at single base-pair
resolution. In addition, a particular location was deemed polymor-
phic if the observed nucleotide count was greater than twice the
count of the actual nucleotide in the reference sequence at that
position. A coverage cutoff of 106 was employed for SNP
identification in clavu7, and all SNPs were verified by Sanger
sequencingofbothwild-type S.clavuligerusand clavu7 DNAusing the
primer sets found in Table S2.
Supporting Information
Figure S1 Images of fourteen evolved S. clavuligerus
control replicates, the starting, unevolved, S. clavuli-
gerus clone, and clavu7 plated against MRSA N315. A.
The fourteen evolved control replicates plated against MRSA
N315. The left panel shows replicates one through seven while the
right panel shows replicates eight through fourteen. These
replicates were evolved for three months as fourteen separate
lineages, but they were not exposed to MRSA N315 until the three
month period ended and this photo was taken. One replicate,
indicated by the arrow, displays a slightly larger ZOI (1–2 mm)
against MRSA N315 than the starting, unevolved clone, but the
other thirteen have ZOIs that are similar or smaller in size. B.
Seven identical colonies of unevolved, wild-type S. clavuligerus
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N315 is approximately 0.5–1 mm. C. Seven identical colonies of
clavu7 plated against MRSA N315. Clavu7 displays a larger ZOI
(2–3 mm) against the pathogen than both the fourteen evolved
control replicates and the starting, unevolved clone. All colonies
seen in each portion of this figure were made by depositing 2 mLo f
an OD600 ,0.1 culture onto the indicated spot on the agar plate,
allowing the colonies to grow for 3 days, and then co-culturing the
colonies with MRSA N315 on the third day. Photos were taken
one day later. Additional images of unevolved S. clavuligerus and
clavu7 can be found in Figure 2 in the main text.
(TIF)
Figure S2 Separation of the compound with m/z 215
(holomycin) from the compound with m/z 388. The
fraction eluting at 11.8 min (see Figure 3A) was collected and re-
injected into the same HPLC system using an optimized mobile
phase (30:70 methanol:water) to yield this new chromatogram and
MS spectra. The flow rate (1.0 mL/min) and detection wavelength
(360 nm) were the same. Under these conditions, select ion
monitoring (SIM) for the holomycin fragments m/z 215 (MS) and
m/z 197 (MS/MS; SRM) revealed that holomycin elutes at
4.6 min while the m/z 388 ion (MS) elutes at 3.5 minutes. The
SIM for m/z 388 was reduced by 1/5 for a better fit in the figure.
Abbreviation: SRM, selected reaction monitoring.
(TIF)
Figure S3 A. High-resolution ESI-MS of holomycin, the bioactive
compound isolated from clavu7. [M+H]
+, observed mass: 214.9941,
calculated mass: 214.9943; [M+Na]
+, observed mass: 236.9761,
calculated mass: 236.9763. B. High-resolution ESI-MS/MS of
holomycin (m/z 214.99) and key MS/MS fragments. There are three
mainpeaks inthedata:[M+H]
+,observedmass: 214.9941,calculated
mass: 214.9943; [M2H2O+H]
+, observed mass: 196.9835, calculat-
ed mass: 196.9838; [M2COCH3+H]
+, observed mass: 172.9836,
calculated mass: 172.9838. A fragmentation mechanism leading to
the latter ion, holothin, has been proposed [55].
(TIF)
Figure S4 PCR amplification of five pSCL4 amplicons
from additional strains evolved against MRSA N315 and
from fourteen evolved control replicates. A. PCR ampli-
fication from evolved strains clavu9, clavu10, NL2-c4, and ReIN.
Clavu9 does not contain the megaplasmid, and a portion of the 59
end is missing from clavu10. Both NL2-c4 and ReIN contain the
full length megaplasmid. B. PCR amplification from fourteen
control replicates evolved in the absence of MRSA N315 over the
same amount of time. All fourteen contain the megaplasmid.
(TIF)
Figure S5 A. Module and domain architecture of S. clavuligerus
ACV synthetase. There are three modules that activate each of the
three amino acids. The first module contains two domains and
initiates biosynthesis of the LLD-ACV tripeptide. The second and
third modules each contain condensation (C) – adenylation (A) –
thiolation (T) domains typically found in many non-ribosomal
peptide synthetases. The final two domains in the third module are
epimerization (E) and thioesterase (Te) domains. The arrow points
to the location of the SNP detected in the clavu7 ACV synthetase.
B. Alignment of the second adenylation domain of S. clavuligerus
ACV synthetase with the amino acid binding pocket within the
GrsA phenylalanine adenylation domain from B. brevis [73]. Based
on the alignment, the L-cysteine binding pocket in ACV synthetase
is predicted to be between residues 1590 and 1690. The putative
V1525L substitution therefore lies within the second adenylation
domain but to the N-terminal side of the predicted binding pocket
[67,68].
(TIF)
Figure S6 Location of the ,27 bp conserved core unit
(underlined) from three putative WD-40 repeats in
SSCG_02612. The proline associated with the C1096T SNP
detected in this gene in clavu7 (Table 1) is shown as well
(highlighted); the SNP results in a P366S amino acid substitution.
The annotation for SSCG_02612 is shorter than that for
SCLAV_2674 (the latter contains an additional 182 amino acids
at the N-terminus), but both have the same reading frame.
(TIF)
Table S1 Primer sets used to PCR amplify five ampli-
cons from pSCL4.
(DOC)
Table S2 Primer sets used to confirm clavu7 SNPs by
Sanger sequencing.
(DOC)
Acknowledgments
We thank Jacqueline Miller and Kathy Andrews for technical contribu-
tions, Lynnie Zhang for assistance with the rotavap, and Tzu-Wen Huang
and Jay Hong for helpful discussions. We thank Christopher Walsh and Bo
Li at Harvard University for providing a sample of pure holomycin.
Author Contributions
Conceived and designed the experiments: PC BOP. Performed the
experiments: PC NLF ARP HJL EAA YS. Analyzed the data: PC HN
ARP YS WHG BOP. Wrote the paper: PC HN ARP YS WHG BOP.
References
1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad
bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of
America. Clin Infect Dis 48: 1–12.
2. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over
the last 25 years. J Nat Prod 70: 461–477.
3. Watve MG, Tickoo R, Jog MM, Bhole BD (2001) How many antibiotics are
produced by the genus Streptomyces? Arch Microbiol 176: 386–390.
4. Wiener P (1996) Experimental studies on the ecological role of antibiotic
production in bacteria. Evolutionary Ecology 10: 405–421.
5. Challis GL, Hopwood DA (2003) Synergy and contingency as driving forces for
the evolution of multiple secondary metabolite production by Streptomyces
species. Proceedings of the National Academy of Sciences of the United States of
America 100 Suppl 2: 14555–14561.
6. Laskaris P, Tolba S, Calvo-Bado L, Wellington EM (2010) Coevolution of
antibiotic production and counter-resistance in soil bacteria. Environmental
microbiology 12: 783–796.
7. Maplestone RA, Stone MJ, Williams DH (1992) The evolutionary role of
secondary metabolites–a review. Gene 115: 151–157.
8. Bentley SD, Chater KF, Cerdeno-Tarraga AM, Challis GL, Thomson NR, et al.
(2002) Complete genome sequence of the model actinomycete Streptomyces
coelicolor A3(2). Nature 417: 141–147.
9. Ikeda H, Ishikawa J, Hanamoto A, Shinose M, Kikuchi H, et al. (2003)
Complete genome sequence and comparative analysis of the industrial
microorganism Streptomyces avermitilis. Nat Biotechnol 21: 526–531.
10. Medema MH, Trefzer A, Kovalchuk A, van den Berg M, Muller U, et al. (2010)
The sequence of a 1.8-mb bacterial linear plasmid reveals a rich evolutionary
reservoir of secondary metabolic pathways. Genome Biol Evol 2: 212–224.
11. Ohnishi Y, Ishikawa J, Hara H, Suzuki H, Ikenoya M, et al. (2008) Genome
sequence of the streptomycin-producing microorganism Streptomyces griseus
IFO 13350. J Bacteriol 190: 4050–4060.
12. Song JY, Jeong H, Yu DS, Fischbach MA, Park HS, et al. (2010) Draft genome
sequence of Streptomyces clavuligerus NRRL 3585, a producer of diverse
secondary metabolites. J Bacteriol 192: 6317–6318.
13. Peiru S, Menzella HG, Rodriguez E, Carney J, Gramajo H (2005) Production of
the potent antibacterial polyketide erythromycin C in Escherichia coli. Appl
Environ Microbiol 71: 2539–2547.
Adaptive Evolution of Sclavu
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e3372714. Mutka SC, Carney JR, Liu Y, Kennedy J (2006) Heterologous production of
epothilone C and D in Escherichia coli. Biochemistry 45: 1321–1330.
15. Hosaka T, Ohnishi-Kameyama M, Muramatsu H, Murakami K, Tsurumi Y, et
al. (2009) Antibacterial discovery in actinomycetes strains with mutations in
RNA polymerase or ribosomal protein S12. Nat Biotechnol 27: 462–464.
16. Kontnik R, Crawford JM, Clardy J (2010) Exploiting a global regulator for small
molecule discovery in Photorhabdus luminescens. ACS Chem Biol 5: 659–665.
17. Bergmann S, Funk AN, Scherlach K, Schroeckh V, Shelest E, et al. (2010)
Activation of a silent fungal polyketide biosynthesis pathway through regulatory
cross talk with a cryptic nonribosomal peptide synthetase gene cluster. Applied
and environmental microbiology 76: 8143–8149.
18. Gottelt M, Kol S, Gomez-Escribano JP, Bibb M, Takano E (2010) Deletion of a
regulatory gene within the cpk gene cluster reveals novel antibacterial activity in
Streptomyces coelicolor A3(2). Microbiology 156: 2343–2353.
19. Laureti L, Song L, Huang S, Corre C, Leblond P, et al. (2011) Identification of a
bioactive 51-membered macrolide complex by activation of a silent polyketide
synthase in Streptomyces ambofaciens. Proceedings of the National Academy of
Sciences of the United States of America 108: 6258–6263.
20. Scherlach K, Schuemann J, Dahse HM, Hertweck C (2010) Aspernidine A and
B, prenylated isoindolinone alkaloids from the model fungus Aspergillus
nidulans. J Antibiot (Tokyo) 63: 375–377.
21. Sanchez S, Chavez A, Forero A, Garcia-Huante Y, Romero A, et al. (2010)
Carbon source regulation of antibiotic production. The Journal of antibiotics 63:
442–459.
22. Garbeva P, Silby MW, Raaijmakers JM, Levy SB, Boer WD (2011)
Transcriptional and antagonistic responses of Pseudomonas fluorescens Pf0-1
to phylogenetically different bacterial competitors. ISME J.
23. Kurosawa K, Ghiviriga I, Sambandan TG, Lessard PA, Barbara JE, et al. (2008)
Rhodostreptomycins, antibiotics biosynthesized following horizontal gene
transfer from Streptomyces padanus to Rhodococcus fascians. J Am Chem
Soc 130: 1126–1127.
24. Slattery M, Rajbhandari I, Wesson K (2001) Competition-Mediated Antibiotic
Induction in the Marine Bacterium Streptomyces tenjimariensis. Microb Ecol
41: 90–96.
25. Bills G, Overy D, Genilloud O, Pelaez F (2009) Contributions of Pharmaceutical
Antibiotic and Secondary Metabolite Discovery to the Understanding of
Microbial Defense and Antagonism. In: White Jr. JF, Torres MS, eds. Defensive
Mutualism in Microbial Symbiosis. Boca Raton, FL: CRC Press. pp 257–297.
26. Oh DC, Kauffman CA, Jensen PR, Fenical W (2007) Induced production of
emericellamides A and B from the marine-derived fungus Emericella sp. in
competing co-culture. Journal of natural products 70: 515–520.
27. Perry MJ, Makins JF, Adlard MW, Holt G (1984) Aspergillic acids produced by
mixed cultures of Aspergillus flavus and Aspergillus nidulans. Journal of general
microbiology 130: 319–323.
28. Sonnenbichler J, Lamm V, Gieren A, Holdenrieder O, Lotter H (1983) A
cyclopentabenzopyranone produced by the fungus Heterobasidion annosum in
dual cultures. Phytochemistry 22: 1489–1491.
29. Baltz RH (2011) Strain improvement in actinomycetes in the postgenomic era.
Journal of industrial microbiology & biotechnology 38: 657–666.
30. Friedman L, Alder JD, Silverman JA (2006) Genetic changes that correlate with
reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrobial
agents and chemotherapy 50: 2137–2145.
31. Banerjee R, Gretes M, Basuino L, Strynadka N, Chambers HF (2008) In vitro
selection and characterization of ceftobiprole-resistant methicillin-resistant
Staphylococcus aureus. Antimicrobial agents and chemotherapy 52: 2089–2096.
32. Locke JB, Hilgers M, Shaw KJ (2009) Novel ribosomal mutations in
Staphylococcus aureus strains identified through selection with the oxazolidi-
nones linezolid and torezolid (TR-700). Antimicrobial agents and chemotherapy
53: 5265–5274.
33. Gilbert DN, Kohlhepp SJ, Slama KA, Grunkemeier G, Lewis G, et al. (2001)
Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae,
and Pseudomonas aeruginosa after single and multiple in vitro exposures to
ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrobial agents and
chemotherapy 45: 883–892.
34. Berger-Bachi B, Strassle A, Kayser FH (1989) Natural methicillin resistance in
comparison with that selected by in-vitro drug exposure in Staphylococcus
aureus. The Journal of antimicrobial chemotherapy 23: 179–188.
35. Woods R, Schneider D, Winkworth CL, Riley MA, Lenski RE (2006) Tests of
parallel molecular evolution in a long-term experiment with Escherichia coli.
Proceedings of the National Academy of Sciences of the United States of
America 103: 9107–9112.
36. Barrick JE, Yu DS, Yoon SH, Jeong H, Oh TK, et al. (2009) Genome evolution
and adaptation in a long-term experiment with Escherichia coli. Nature 461:
1243–1247.
37. Conrad TM, Joyce AR, Applebee MK, Barrett CL, Xie B, et al. (2009) Whole-
genome resequencing of Escherichia coli K-12 MG1655 undergoing short-term
laboratory evolution in lactate minimal media reveals flexible selection of
adaptive mutations. Genome Biol 10: R118.
38. Herring CD, Raghunathan A, Honisch C, Patel T, Applebee MK, et al. (2006)
Comparative genome sequencing of Escherichia coli allows observation of
bacterial evolution on a laboratory timescale. Nat Genet 38: 1406–1412.
39. Charusanti P, Conrad TM, Knight EM, Venkataraman K, Fong NL, et al.
(2010) Genetic basis of growth adaptation of Escherichia coli after deletion of
pgi, a major metabolic gene. PLoS Genet 6: e1001186.
40. Auriol C, Bestel-Corre G, Claude JB, Soucaille P, Meynial-Salles I (2011) Stress-
induced evolution of Escherichia coli points to original concepts in respiratory
cofactor selectivity. Proceedings of the National Academy of Sciences of the
United States of America 108: 1278–1283.
41. Horinouchi T, Tamaoka K, Furusawa C, Ono N, Suzuki S, et al. (2010)
Transcriptome analysis of parallel-evolved Escherichia coli strains under ethanol
stress. BMC genomics 11: 579.
42. Wang Y, Manow R, Finan C, Wang J, Garza E, et al. (2011) Adaptive evolution
of nontransgenic Escherichia coli KC01 for improved ethanol tolerance and
homoethanol fermentation from xylose. Journal of industrial microbiology &
biotechnology 38: 1371–1377.
43. Stanley D, Fraser S, Chambers PJ, Rogers P, Stanley GA (2010) Generation and
characterisation of stable ethanol-tolerant mutants of Saccharomyces cerevisiae.
Journal of industrial microbiology & biotechnology 37: 139–149.
44. Stoebel DM, Hokamp K, Last MS, Dorman CJ (2009) Compensatory evolution
of gene regulation in response to stress by Escherichia coli lacking RpoS. PLoS
genetics 5: e1000671.
45. Tremblay PL, Summers ZM, Glaven RH, Nevin KP, Zengler K, et al. (2011) A
c-type cytochrome and a transcriptional regulator responsible for enhanced
extracellular electron transfer in Geobacter sulfurreducens revealed by adaptive
evolution. Environmental microbiology 13: 13–23.
46. Trinh CT, Srienc F (2009) Metabolic engineering of Escherichia coli for efficient
conversion of glycerol to ethanol. Applied and environmental microbiology 75:
6696–6705.
47. Hu H, Wood TK (2010) An evolved Escherichia coli strain for producing
hydrogen and ethanol from glycerol. Biochemical and biophysical research
communications 391: 1033–1038.
48. Wang ES, Dobrikova E, Goetz C, Dufresne AT, Gromeier M (2011) Adaptation
of an ICAM-1-tropic enterovirus to the mouse respiratory tract. Journal of
virology 85: 5606–5617.
49. Hughes GJ, Mioulet V, Haydon DT, Kitching RP, Donaldson AI, et al. (2002)
Serial passage of foot-and-mouth disease virus in sheep reveals declining levels of
viraemia over time. The Journal of general virology 83: 1907–1914.
50. Locher CP, Witt SA, Herndier BG, Abbey NW, Tenner-Racz K, et al. (2003)
Increased virus replication and virulence after serial passage of human
immunodeficiency virus type 2 in baboons. Journal of virology 77: 77–83.
51. Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, et al. (2001) Whole
genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet 357:
1225–1240.
52. Khare A, Santorelli LA, Strassmann JE, Queller DC, Kuspa A, et al. (2009)
Cheater-resistance is not futile. Nature 461: 980–982.
53. Kenig M, Reading C (1979) Holomycin and an antibiotic (MM 19290) related
to tunicamycin, metabolites of Streptomyces clavuligerus. J Antibiot (Tokyo) 32:
549–554.
54. de la Fuente A, Lorenzana LM, Martin JF, Liras P (2002) Mutants of
Streptomyces clavuligerus with disruptions in different genes for clavulanic acid
biosynthesis produce large amounts of holomycin: possible cross-regulation of
two unrelated secondary metabolic pathways. J Bacteriol 184: 6559–6565.
55. Okamura K, Soga K, Shimauchi Y, Ishikura T, Lein J (1977) Holomycin and N-
propionylholothin, antibiotics produced by a cephamycin C producer. J Antibiot
(Tokyo) 30: 334–336.
56. Kirby R (1978) An Unstable Genetic Element Affecting the Production of the
Antibiotic Holomycin by Streptomyces Clavuligerus. FEMS Microbiol Lett 3:
283–286.
57. Liras P, Demain AL (2009) Chapter 16. Enzymology of beta-lactam compounds
with cephem structure produced by actinomycete. Methods Enzymol 458:
401–429.
58. Li B, Walsh CT (2010) Identification of the gene cluster for the dithiolopyrrolone
antibiotic holomycin in Streptomyces clavuligerus. Proc Natl Acad Sci U S A
107: 19731–19735.
59. Hardin G (1960) The competitive exclusion principle. Science 131: 1292–1297.
60. Gause GF The Struggle for Existence: Williams & Wilkins.
61. Gause GF (1932) Experimental studies on the struggle for existence. Journal of
experimental biology 9: 389–402.
62. Oliva B, O’Neill A, Wilson JM, O’Hanlon PJ, Chopra I (2001) Antimicrobial
properties and mode of action of the pyrrothine holomycin. Antimicrob Agents
Chemother 45: 532–539.
63. Puehringer S, Metlitzky M, Schwarzenbacher R (2008) The pyrroloquinoline
quinone biosynthesis pathway revisited: a structural approach. BMC biochem-
istry 9: 8.
64. Cozier GE, Anthony C (1995) Structure of the quinoprotein glucose
dehydrogenase of Escherichia coli modelled on that of methanol dehydrogenase
from Methylobacterium extorquens. The Biochemical journal 312(Pt 3):
679–685.
65. Anthony C (2000) Methanol dehydrogenase, a PQQ-containing quinoprotein
dehydrogenase. Sub-cellular biochemistry 35: 73–117.
66. Nowak-Thompson B, Chaney N, Wing JS, Gould SJ, Loper JE (1999)
Characterization of the pyoluteorin biosynthetic gene cluster of Pseudomonas
fluorescens Pf-5. Journal of bacteriology 181: 2166–2174.
67. Challis GL, Ravel J, Townsend CA (2000) Predictive, structure-based model of
amino acid recognition by nonribosomal peptide synthetase adenylation
domains. Chem Biol 7: 211–224.
Adaptive Evolution of Sclavu
PLoS ONE | www.plosone.org 11 March 2012 | Volume 7 | Issue 3 | e3372768. Stachelhaus T, Mootz HD, Marahiel MA (1999) The specificity-conferring code
of adenylation domains in nonribosomal peptide synthetases. Chem Biol 6:
493–505.
69. Smith TF, Gaitatzes C, Saxena K, Neer EJ (1999) The WD repeat: a common
architecture for diverse functions. Trends in biochemical sciences 24: 181–185.
70. Li D, Roberts R (2001) WD-repeat proteins: structure characteristics, biological
function, and their involvement in human diseases. Cellular and molecular life
sciences : CMLS 58: 2085–2097.
71. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF (1994) The ancient
regulatory-protein family of WD-repeat proteins. Nature 371: 297–300.
72. Kronstad JW, Attarian R, Cadieux B, Choi J, D’Souza CA, et al. (2011)
Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic
box. Nature reviews Microbiology 9: 193–203.
73. Conti E, Stachelhaus T, Marahiel MA, Brick P (1997) Structural basis for the
activation of phenylalanine in the non-ribosomal biosynthesis of gramicidin S.
EMBO J 16: 4174–4183.
Adaptive Evolution of Sclavu
PLoS ONE | www.plosone.org 12 March 2012 | Volume 7 | Issue 3 | e33727